Categories Technology

Cognizant is hell-bent on tapping the US healthcare sector, will buy Bolder Healthcare

Healthcare seems to be the keyword for tech companies these days, with most including Apple bringing out products and services to improve the longevity of mankind (God, save our users!).  IT-services major Cognizant is now expanding its reach into the healthcare sector with its intention to acquire Bolder Healthcare Solutions.

Bolder is a private firm that offers revenue cycle management solutions to hospitals and specialty care providers. Through this transaction, which is expected to close in the second quarter of the year, Cognizant plans to expand its services to more hospitals and healthcare providers.

Bolder acquisition will create value for all the shareholders, as a report from Zion Market Research indicated,  the global revenue cycle management is expected to grow to around $43.80 billion by 2022 from $23.40 billion in 2016. Also, a major chunk of the market share is expected to come from North America, which poses an enormous advantage for Cognizant as over 70% of its revenue is derived from this region.

IT-services major Cognizant is now expanding its reach into the healthcare sector with its intention to acquire Bolder Healthcare Solutions. 

Cognizant derives most of its revenue from two industries: Financial services and healthcare business. Over the past few years, Cognizant has been pretty serious with its healthcare business, as it accounts for almost 30% of the company’s total revenue. In the latest fourth quarter, the company reported 12% growth in its revenue from healthcare business.

Cognizant’s largest healthcare deal occurred in 2014 when the company purchased TriZetto for $2.7 billion, which was followed by the acquisition of TMG Health.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top